HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunity, Weight Loss Supplement Marketers Risk FTC Scrutiny By Ignoring Industry Self-Regulation

Executive Summary

NAD forwards to regulatory agency its concerns about claims by Hypernatural and Letitox Nutrition after they didn’t participate in the industry self-regulation forum. Both firms’ claims were challenged by the Council for Responsible Nutrition as part of a program with NAD it previously supported.

You may also be interested in...



Risking FTC Scrutiny, Direct Seller Ignores Industry Self-Regulation Group On COVID-19 Claims

Direct seller Flavon USA is referred to FTC after it failed to respond to repeated outreach by Direct Selling Self-Regulatory Council over claims its supplements treat coronavirus. The watchdog asked for substantiation of claims suggesting products also could tumors and diabetes.

FTC Does Advertising Law Enforcement, Not Second Chances For Ad Claims Arbitration

Some firms that challenged ad claims NAD attorneys later bring to FTC's attention want to take more shots at the claims while businesses making the claims want to repeat their arguments from NAD reviews, says Carolyn Hann, FTC chief of staff for advertising practices.

CRN Ends Funding For Industry Self-Regulation Program Focused On Supplement Advertising

The trade group ends funding for National Advertising Division program launched in 2006 for increased focus on monitoring supplement claims, reviewing 360 in total. Separately, NAD launches an expedited challenge process aiming to conclude reviews in 20 business days.

Topics

UsernamePublicRestriction

Register

RS150529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel